Current Atherosclerosis Reports

Papers
(The TQCC of Current Atherosclerosis Reports is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions Towards Healthcare Equity87
APOA1: a Protein with Multiple Therapeutic Functions85
Food Insecurity and Cardiovascular Disease Risk81
Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease74
COVID and Cardiovascular Disease: What We Know in 202171
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?61
High-Density Lipoproteins and Serum Amyloid A (SAA)58
Time-Restricted Eating to Improve Cardiovascular Health52
Lipid Lowering Drugs: Present Status and Future Developments48
Statins and Inflammation45
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets44
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician44
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues44
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond38
Bempedoic Acid: for Whom and When38
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis37
Phytosterols and Cardiovascular Disease35
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?34
Overweight, Obesity, and CVD Risk: a Focus on Visceral/Ectopic Fat32
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context31
Understanding Immigration as a Social Determinant of Health: Cardiovascular Disease in Hispanics/Latinos and South Asians in the United States28
Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis28
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease27
HDL-small RNA Export, Transport, and Functional Delivery in Atherosclerosis27
High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis26
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics26
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?25
Apolipoprotein E and Atherosclerosis25
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors25
Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease24
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease24
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis24
Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents23
The Genetic Basis of Hypertriglyceridemia23
RNA Silencing in the Management of Dyslipidemias22
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men22
The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes22
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?22
Obesity and Dyslipidemia21
The Role of High-Density Lipoprotein Cholesterol in 202221
Ambient Air Pollution and Atherosclerosis: Recent Updates21
LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective21
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases21
A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke20
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis20
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice20
Lipoprotein (a): When to Measure and How to Treat?20
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis20
Lp(a): a New Pathway to Target?20
Sex Differences in Coronary Atherosclerosis20
Lipid Phenotypes and DNA Methylation: a Review of the Literature19
Inclisiran: How Widely and When Should We Use It?19
Metabolomic Biomarkers of Healthy Dietary Patterns and Cardiovascular Outcomes19
Childhood Obesity and Cardiovascular Disease Risk19
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?18
The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis18
MicroRNAs and Circular RNAs in Lipoprotein Metabolism18
Lipoprotein (a): Recent Updates on a Unique Lipoprotein17
Contributions of Food Environments to Dietary Quality and Cardiovascular Disease Risk17
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management17
Novel RNAi-Based Therapies for Atherosclerosis17
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?17
Obesity Management in Cardiometabolic Disease: State of the Art17
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators17
Updates in Drug Treatment of Severe Hypertriglyceridemia16
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism16
Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)16
Hypertension in Women Across the Lifespan16
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)16
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–202016
Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies15
Free Cholesterol Bioavailability and Atherosclerosis15
Managing Ischemic Heart Disease in Women: Role of a Women’s Heart Center15
The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular Health15
Dietary Influences on Atherosclerotic Cardiovascular Disease Risk14
Gene-Environment Interactions for Cardiovascular Disease14
A Nutrigenetic Update on CETP Gene–Diet Interactions on Lipid-Related Outcomes13
The Role of Calorie Restriction in the Prevention of Cardiovascular Disease13
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor13
Novel Functions of Endothelial Scavenger Receptor Class B Type I13
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future12
Coconut Oil and Cardiovascular Disease Risk12
Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia12
How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?12
Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?12
Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime12
Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia12
0.054319858551025